Top Page
Control Bionics Ltd.
(Sydney:CBL)
Control Bionics Ltd. (CBL) vs. S&P 500 (SPY)
Control Bionics Ltd. Business Overview & Revenue Model
Control Bionics Ltd. Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 5.13M | 5.44M | 4.38M | 3.93M | 3.10M | Gross Profit |
| 3.67M | 3.50M | 2.40M | 2.50M | 215.51K | EBIT |
| -5.93M | -5.62M | -6.09M | -3.52M | -1.20M | EBITDA |
| -5.01M | -5.14M | -5.58M | -3.40M | -989.96K | Net Income Common Stockholders |
| -5.91M | -5.63M | -6.11M | -4.19M | -1.01M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 980.76K | 935.50K | 5.21M | 12.33M | 15.60M | Total Assets |
| 9.03M | 8.70M | 13.44M | 18.35M | 20.51M | Total Debt |
| 961.74K | 128.50K | 284.82K | 14.87K | 46.00K | Net Debt |
| -19.02K | -807.00K | -4.93M | -12.32M | -15.55M | Total Liabilities |
| 2.76M | 1.55M | 1.51M | 1.19M | 387.00K | Stockholders Equity |
| 6.27M | 7.15M | 11.92M | 17.16M | 20.13M |
| Cash Flow | Free Cash Flow | |||
| -5.38M | -4.98M | -5.75M | -4.04M | -1.17M | Operating Cash Flow |
| -4.91M | -4.53M | -5.60M | -3.99M | -864.05K | Investing Cash Flow |
| -473.09K | -457.54K | -147.74K | -53.40K | -301.85K | Financing Cash Flow |
| 5.43M | 706.43K | -87.33K | 14.92M | 1.79M |
Control Bionics Ltd. Technical Analysis
Control Bionics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$16.55M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
55 Neutral | $884.28M | 148.84 | 8.30% | ― | 39.19% | 273.91% | |
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% | |
50 Neutral | AU$714.49M | ― | -112.97% | ― | ― | -84.82% | |
46 Neutral | AU$3.86M | ― | -392.18% | ― | ― | 34.11% | |
38 Underperform | AU$11.49M | ― | -98.08% | ― | -7.44% | 30.34% | |
35 Underperform | AU$5.02M | ― | ― | -67.78% | 37.66% |
Control Bionics Ltd. Corporate Events
Control Bionics Limited announced an investor webinar to discuss its quarterly results and recent advancements. The company is enhancing its market position with innovative products like the NeuroNode and DROVE, and is expanding into new sectors with the NeuroStrip®, potentially impacting its operations and stakeholder interests.
Control Bionics Ltd. announced the cessation of Peter Ford as a director effective March 31, 2025. Ford held a significant number of ordinary shares, totaling 20,003,433, which may influence the company’s shareholder dynamics. This change in directorship could impact the company’s strategic direction and governance, potentially affecting stakeholders’ interests.
Control Bionics Ltd has announced the appointment of Stephanie Phillips as a director effective March 25, 2025. Phillips holds significant interests in the company, with 149,998 ordinary shares registered in her name and an additional 3,700,000 shares held through Ironwood Investments Pty Ltd. This appointment and Phillips’ substantial shareholding could influence the company’s strategic direction and strengthen its market position.
Control Bionics Limited has announced the appointment of Dr. Stephanie Phillips to its Board of Directors, bringing her extensive experience in anaesthesia and critical care to the company. Her expertise is expected to significantly contribute to Control Bionics’ expansion into new markets in assistive communication, rehabilitation, and health diagnostics. Concurrently, the company announced the resignation of its founder, Peter Ford, from the Board, effective March 31, 2025. Ford’s pioneering work led to the development of the NeuroNode technology, which has been transformative in the assistive technology sector. While stepping down, Ford remains a significant shareholder, ensuring his continued influence on the company’s future.
Control Bionics Ltd. has announced a significant change in the interests of its substantial holder, Nightingale Partners Pty Ltd, which has increased its voting power from 13.52% to 19.10% through an off-market purchase and placement. This change in substantial holding could impact the company’s strategic decisions and influence its market positioning, potentially affecting stakeholders and future company operations.
Control Bionics Ltd. announced the issuance of 42,624,175 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. This move indicates the company’s compliance with relevant legal provisions, potentially strengthening its financial position and signaling confidence in its market strategy.
Control Bionics Ltd. has announced the application for the quotation of 42,624,175 fully paid ordinary securities on the ASX, as part of a transaction previously disclosed to the market. This move is expected to enhance the company’s financial flexibility and potentially improve its market positioning, offering stakeholders an opportunity to engage with the company’s growth trajectory.
Control Bionics Limited reported a 2.3% decrease in revenues from ordinary activities for the half-year ended December 31, 2024, totaling $2,896,291. The company also experienced a significant increase in its loss from ordinary activities after tax, which rose by 47.12% to $3,222,197. No dividends were declared during this period. The financial results indicate challenges in improving profitability, which may impact the company’s strategic initiatives and stakeholder confidence.
Control Bionics Ltd. announced a proposed issue of 42,624,175 fully paid ordinary securities, scheduled for February 26, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s financial standing and market positioning by increasing its capital base, which could be used for further development and expansion of its product offerings.
Control Bionics Limited has successfully raised approximately A$2 million through a private placement to support its growth initiatives, particularly in expanding its NeuroNode and NeuroStrip product lines. This capital infusion is expected to enhance the company’s operational execution, accelerate commercialization efforts, and drive long-term shareholder value, positioning it for future growth in core and emerging markets.